secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274405
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista reports $13.7M Q3 net product revenue from EKTERLY launch; 937 patient start forms through Oct
--------------------------------------------------------------------------------

- Net product revenue of $13.7M for Q3 ended Sept 30, 2025, first full quarter of EKTERLY commercial launch.
- 937 patient start forms received and 423 unique prescribers activated through Oct 31, 2025.
- Cash and marketable securities of $309.2M; expects to fund through profitability.
- EKTERLY approved in EU, Switzerland, and Australia; Germany launch initiated Oct 2025.
- R&D expenses $12.0M (down from $18.7M); SG&A $46.5M (up from $24.8M) due to commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525274405/0001193125-25-274405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525274405/d43801d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer